Hematology / Oncology @Point of Care Podcasts
Episodes
S28:E2 – Randomized Controlled Trials and Real-World Evidence: Efficacy Across Patient Subgroups with LR-MDS
24 Apr 2026
Contributed by Lukas
In this podcast episode, Andrew Kuykendall, MD, and Sangeetha Venugopal, MD, MS they review the clinical trial and real-world evidence on the efficacy...
S28:E1 – Clearing the Confusion on Dosing for Luspatercept in LR-MDS
24 Apr 2026
Contributed by Lukas
In this podcast episode, Andrew Kuykendall, MD, and Sangeetha Venugopal, MD, MS explore dose escalation strategies for the erythroid maturation agen...
S27:E3 – Treating NSCLC Without Actionable Mutations: The Role of TROP2 ADCs
15 Jan 2026
Contributed by Lukas
In this episode, our expert faculty, medical oncologist Dr. Heather Wakelee, and pathologist Dr. Anil Parwani, explore targeted antibody-drug conjugat...
S27:E2 – TROP2-Directed ADCs in EGFR-Mutated NSCLC: What Comes After Osimertinib
15 Jan 2026
Contributed by Lukas
In this episode, Dr. Charu Aggarwal and Dr. Heather Wakelee explore targeted antibody-drug conjugates (ADCs) in the management of EGFR-mutated NSCLC. ...
S27:E1 – HER2-Directed ADCs in Advanced NSCLC
15 Jan 2026
Contributed by Lukas
In this episode, medical oncologist Dr. Charu Aggarwal and nurse practitioner Beth Sandy explore human epidermal growth factor receptor 2 (HER2)-direc...
S26:E3 – Rewriting the ET Playbook
31 Oct 2025
Contributed by Lukas
In this episode, Rewriting the ET Playbook, Dr. Douglas Tremblay and Dr. Ruben Mesa review the current therapeutic options for treating essential thro...
S26:E2 – Treatment Success in PV
31 Oct 2025
Contributed by Lukas
In this episode, Treatment Success in PV, Dr. Douglas Tremblay and Dr. Ruben Mesa focus on the goals of therapy for polycythemia vera, namely improvin...
S26:E1 – From Clues to Classification: PV and ET Diagnosis and Risk Stratification
31 Oct 2025
Contributed by Lukas
In this episode, From Clues to Classification, PV and ET Diagnosis Risk Stratification, Dr. Douglas Tremblay and Dr. Ruben Mesa discuss how clinicians...
S25:E2 – Managing RET Fusion-Positive NSCLC
14 Jul 2025
Contributed by Lukas
In this episode, our faculty, Dr. Justin F. Gainor and Elizabeth A. Krueger, CNP, discuss practical and evidence-based strategies for managing patient...
S25:E1 – ALK-Positive NSCLC: Navigating the Treatment Landscape
14 Jul 2025
Contributed by Lukas
In this episode, our faculty, Dr. Charu Aggarwal and Beth Sandy, MSN, CRNP, FAPO, discuss biomarker testing, first-line treatment decisions, including...
S24:E3 – Evidence-Based Strategies for Individualizing CAR T-Cell Therapy in Patients With RRMM
27 Jun 2025
Contributed by Lukas
In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, discuss what clinicians need to know about optimizing treatment str...
S24:E2 – Identifying Patients for CAR T-Cell Therapy in Earlier Treatment Lines for RRMM
27 Jun 2025
Contributed by Lukas
In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, discuss patient selection. Who is the ideal candidate for chimeric ...
S24:E1 – CAR T-Cell Therapy Earlier in Treatment for RRMM
27 Jun 2025
Contributed by Lukas
In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, explore shifting CAR T-cell therapy into earlier lines of treatment...
S23:E3 – Staying the Course in Metastatic Breast Cancer
21 Jun 2025
Contributed by Lukas
In this episode, Staying the Course in Metastatic Breast Cancer, Dr. Joyce O’Shaughnessy and Marissa Marti-Smith talk about the importance of shared...
S23:E2 – Mapping the Pathway in Metastatic Breast Cancer
21 Jun 2025
Contributed by Lukas
In this episode, Mapping the Pathway in Metastatic Breast Cancer, Dr. Joyce O’Shaughnessy and Dr. Reshma Mahtani take a deeper dive into the phospha...
S23:E1 – Testing the Waters in Metastatic Breast Cancer
21 Jun 2025
Contributed by Lukas
In this episode, Testing the Waters in Metastatic Breast Cancer, Dr. Joyce O’Shaughnessy and Dr. Michelle Shiller discuss biomarkers and the best pr...
S22:E3 – Compare Your TROP2-directed ADC in Non-Small Cell Lung Cancer Treatment-Related Adverse Events Management Plan to the Experts
31 May 2025
Contributed by Lukas
In this episode, our Faculty, Dr. Charu Aggarwal and Dr. Jacob Sands, explore the clinical impact of investigational TROP2-directed antibody-drug conj...
S22:E2 – Advances in TROP2-directed ADCs for Non-Small Cell Lung Cancer: First-Line and Combination Therapies
31 May 2025
Contributed by Lukas
In this episode, our Faculty, Dr. Charu Aggarwal and Dr. Jacob Sands, discuss ongoing clinical trials, evolving biomarker approaches using Quantitativ...
S22:E1 – TROP2-directed ADCs in the Second Line: Updates from Clinical Trials in NSCLC
31 May 2025
Contributed by Lukas
In this episode, our Faculty, Dr. Charu Aggarwal and Dr. Jacob Sands, explore the evolving landscape of TROP2-directed antibody-drug conjugates in sec...
S21:E2 – Individualizing Care Plans for Patients With AML
30 Sep 2024
Contributed by Lukas
In this episode, Individualizing Care Plans for Patients With AML, Dr. Amer Zeidan and Dr. Guillermo Garcia-Manero discuss how to incorporate evidence...
S21:E1 – Improving Survival With HMA Maintenance Therapy in AML
30 Sep 2024
Contributed by Lukas
In this episode, Improving Survival With HMA Therapy in AML, Dr. Amer Zeidan and Dr. Guillermo Garcia-Manero discuss the latest clinical trial evidenc...
S20:E3 – Identifying and Managing Treatment-Related Adverse Events (TRAEs) Associated With TROP2-Targeting Therapies
29 Jan 2024
Contributed by Lukas
In this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinician...
S20:E1 – Clinical Implications of Trophoblast-Cell Surface Antigen 2 (TROP2) in Non-Small Cell Lung Cancer (NSCLC)
29 Jan 2024
Contributed by Lukas
In this episode, Clinical Implications of Trophoblast-Cell Surface Antigen 2 in Non-Small Cell Lung Cancer, Dr. Justin Gainor and Dr. Helena Yu discus...
S20:E2 – Latest Clinical Trial Data of Emerging, TROP2-Targeting Agents in Advanced NSCLC
29 Jan 2024
Contributed by Lukas
In this episode our faculty look at some of the clinical data on anti-Trop-2 treatments and why they may be heralding an exciting future for the treat...
S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer
29 Dec 2023
Contributed by Lukas
Our faculty continue their discussion about clinical trials of HER3-directed therapies with a look at treatment-related adverse events and how to mana...
S19:E2 – Morning Commute Podcast: A Review of Trial Data on HER3 in Non-Small Cell Lung Cancer and Breast Cancer
29 Dec 2023
Contributed by Lukas
In this episode our faculty take a look at the clinical trial data on HER3-directed therapies for breast and lung cancer. Visit www.morningcommutepodc...
S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer?
29 Dec 2023
Contributed by Lukas
In this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinician...
S18:E3 – Morning Commute Podcast: Biomarker Testing in HR+ Breast Cancer—If the Shoe Fits
30 Nov 2023
Contributed by Lukas
In this episode our faculty take a look at the ins and outs of molecular testing in patients with HR+ positive breast cancer. Visit www.morningcommute...
S18:E2 – Morning Commute Podcast: Embracing HER2-Low, Trop2-Directed, and Other Newer Approaches to HR-Positive Breast Cancer
30 Nov 2023
Contributed by Lukas
In this podcast, our faculty take a look at some of the clinical data behind the newer treatment strategies for HR-positive breast cancer as well as h...
S18:E1 – Morning Commute Podcast: An AKTor and Supporting Cast Take the Stage in HR+ Breast Cancer
30 Nov 2023
Contributed by Lukas
In this podcast, our faculty discuss some newer treatment approaches for patients with HR-positive breast cancer including PI3K inhibition, AKT inhibi...
S17:E4 – Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia
15 Nov 2023
Contributed by Lukas
FLT3-inhibitors, such as quizartinib, are changing the treatment paradigm for AML, in this podcast, our faculty take a look at the drug class, how the...
S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib
15 Nov 2023
Contributed by Lukas
The treatment paradigm for the treatment of AML is changing. In this podcast, our faculty discuss quizartinib and the QuANTUM-First trial. Visit www...
S17:E2 – Morning Commute Podcast: Treatment Options for Newly Diagnosed AML Patients
15 Nov 2023
Contributed by Lukas
In this podcast our faculty discuss the latest treatment options for AML that target FLT3 mutations: midostaurin, gilteritinib, and the new kid on the...
S17:E1 – Morning Commute Podcast: The Molecular Landscape of FLT3 Mutations in AML
15 Nov 2023
Contributed by Lukas
Our faculty discuss the importance of biomarker testing for FLT3 and FLT3-ITD and the prognostic impact for these patients, especially now that there ...
S16:E3 – Oncology Morning Commute: Sequencing Therapies in Endometrial Cancer Beyond the First-line Setting
26 Jul 2023
Contributed by Lukas
In this podcast of our three-part series, our faculty continue their discussion on the treatment of endometrial cancer, this time looking at some of t...
S16:E2 – Oncology Morning Commute: Is Immunotherapy Replacing Chemo in the First-Line Treatment Setting for Endometrial Cancer?
31 Dec 2022
Contributed by Lukas
In this episode of our three-part series on endometrial cancer, our faculty continue their discussion by turning to some of the ongoing, and some may ...
S16:E1 – Oncology Morning Commute: Understanding the Heterogeneity of Endometrial Cancer
31 Dec 2022
Contributed by Lukas
In this podcast, our faculty discuss the heterogeneity of endometrial cancer and its four molecular classifications. How do these classifications help...
S15:E3 – Oncology Morning Commute: HER2+ CRC Therapies in Clinical Practice
23 Dec 2022
Contributed by Lukas
In this final podcast of our 3-part series, our faculty take their discussion of metastatic colorectal cancer and HER2-targeted therapies to the clini...
S15:E2 – Oncology Morning Commute: Emerging Data on HER2-Positive Colorectal Cancer Therapies
23 Dec 2022
Contributed by Lukas
In this podcast, our faculty discuss HER2-positive colorectal cancer. HER2 has long been associated as a biomarker and treatment target for breast can...
S15:E1 – Oncology Morning Commute: Recognition of Actionable Biomarkers in Colorectal Cancer
23 Dec 2022
Contributed by Lukas
In this first podcast of our three-part series, our faculty discuss biomarkers for colorectal cancer including HER2. Are you aware of the current guid...
S14:E3 – Oncology Morning Commute: How Can Physicians Use Best Clinical Judgment to Determine Core Drivers for Cancer Screening?
22 Dec 2022
Contributed by Lukas
In this final podcast of our 3-part series, our faculty continue their discussion on multicancer early detection tests, this time turning to how to in...
S14:E2 – Oncology Morning Commute: A Review of the Science Behind Multicancer Early Detection Tests
22 Dec 2022
Contributed by Lukas
In the second episode of our podcast series on early cancer detection, our faculty take a closer look at multicancer early detection tests and the gro...
S14:E1 – Oncology Morning Commute: New Approaches to Testing Patients for Cancer
22 Dec 2022
Contributed by Lukas
In this podcast, our faculty discuss new methods of detecting cancer, including liquid biopsy and blood based, multicancer early detection tests. Can ...
S13:E3 – Oncology Morning Commute: What’s Next in Using PARP Inhibitors for Patients With Ovarian Cancer?
16 Dec 2022
Contributed by Lukas
In this final podcast of our three-part series, our faculty look at some of the latest findings on PARP inhibitors as well as what is on the horizon. ...
S13:E2 – Oncology Morning Commute: Managing Adverse Events That Occur With PARP Inhibition Therapies—What Your Patients Need to Know
16 Dec 2022
Contributed by Lukas
In this podcast, our faculty continue their discussion about PARP inhibitors and take it down to the clinical level. Who are the best candidates for t...
S13:E1 – Oncology Morning Commute: Patient Selection for Treatment With PARP Inhibitors in Ovarian Cancer
16 Dec 2022
Contributed by Lukas
What is the history behind the development of PARP inhibitors for the treatment of ovarian cancer and how have they influenced recent guideline change...
S12:E3 – Oncology Morning Commute: Shifting Treatment Sequences in the Relapsed or Refractory Diffuse Large B-Cell Lymphoma Landscape
23 Nov 2022
Contributed by Lukas
In the final episode of our series, our faculty discuss the changing treatment landscape for diffuse large B-cell lymphoma. With more and more options...
S12:E2 – Oncology Morning Commute: Antibody-Drug Conjugates and the Changing Relapsed or Refractory Diffuse Large B-Cell Lymphoma Landscape
23 Nov 2022
Contributed by Lukas
What are the antibody-drug conjugate treatment options for patients with relapsed or refractory diffuse large B-cell lymphoma? In this podcast our fac...
S12:E1 – Oncology Morning Commute: A Primer on B-Cell Targets in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
23 Nov 2022
Contributed by Lukas
In this podcast, our faculty discuss relapsed/refractory diffuse large B-cell lymphoma, how refractory disease is defined, and the role of the new ant...
S11:E6 – Oncology Morning Commute: Have I Got a Follicular Lymphoma Trial for You
01 Oct 2022
Contributed by Lukas
In this final episode, our faculty discuss clinical trials that are in progress, the importance of the clinical trial process, and how they benefit pa...
S11:E5 – Oncology Morning Commute: Safety First in Follicular Lymphoma
01 Oct 2022
Contributed by Lukas
In this podcast, our faculty discuss the major classes of treatment for follicular lymphoma, including outcomes and managing the expected toxicities. ...
S11:E4 – Oncology Morning Commute: Making the Case for Follicular Lymphoma Therapy
01 Oct 2022
Contributed by Lukas
How is the best way to select and sequence follicular lymphoma therapies? In this episode, our faculty discuss this and more. Visit http://www.Morning...
S11:E3 – Oncology Morning Commute: Follicular Lymphoma—Haven't We Met Before?
01 Oct 2022
Contributed by Lukas
In our third podcast in this series, our faculty take a look at third-line treatment options for follicular lymphoma patients. Visit http://www.Mornin...
S11:E2 – Oncology Morning Commute: What Can We Do About Early Relapsing Follicular Lymphoma?
01 Oct 2022
Contributed by Lukas
In this second podcast of our series, our faculty continue their discussion of follicular lymphoma and its treatment, particularly for those patients ...
S11:E1 – Oncology Morning Commute: Follicular Lymphoma: A New Patient Walks Into The Clinic
01 Oct 2022
Contributed by Lukas
What are the initial treatment strategies for the newly diagnosed patient with follicular lymphoma? Our faculty discuss this and more in this first ep...
S9:E2 – Oncology Journal Club: How Covid Treatment Advances are Helping CLL Patients
25 Jul 2022
Contributed by Lukas
There is some good news for preventing and treating Covid in patients with chronic lymphocytic leukemia (CLL). New treatment advances allow clinicians...
S10:E5 – Oncology Morning Commute: Toxicity Risks and the New-Generation Treatments for CML
15 May 2022
Contributed by Lukas
As with any treatment, toxicities can be a concern. Our faculty return to discuss toxicities with third-generation tyrosine kinase inhibitors. How can...
S10:E4 – Oncology Morning Commute: Keeping Watch—Treatment Response in CML
15 May 2022
Contributed by Lukas
What are the treatment response benchmarks when treating chronic myeloid leukemia and when, if ever, should therapies be switched? Moreover, how do yo...
S10:E3 – Oncology Morning Commute: Dialing Down—Optimizing Third-Generation Treatments for CML
15 May 2022
Contributed by Lukas
When treating patients with chronic myeloid leukemia with BCR-ABL1 tyrosine kinase inhibitors, what is the optimal dose? Our faculty discuss this as w...
S10:E2 – Oncology Morning Commute: Targeting STAMP in CML
15 May 2022
Contributed by Lukas
In this podcast our faculty return for a discussion of a new target for the treatment of chronic myeloid leukemia and the newest treatment on the bloc...
S10:E1 – Oncology Morning Commute: Third-Line Treatment of CML
15 May 2022
Contributed by Lukas
Third-line treatment of chronic myeloid leukemia and in particular BCR-ABL1 tyrosine kinase inhibitors are the latest therapeutics in the clinician’...
S9:E1 – Oncology Journal Club: Covid-19 and CLL Implications for Treatment Decision-Making
15 May 2022
Contributed by Lukas
How is the Covid-19 pandemic affecting patients with chronic lymphocytic leukemia (CLL)? Our faculty discuss several papers during this podcast that a...
S8:E3 – Oncology Morning Commute: ADCs for NSCLC—Ready for Prime Time?
28 Mar 2022
Contributed by Lukas
Our faculty discuss exciting developments in targeted therapies for non-small cell lung cancer, specifically the promise of antibody-drug conjugates a...
S8:E2 – Oncology Morning Commute: PD-L1 Expression in NSCLC
28 Mar 2022
Contributed by Lukas
Our faculty takes a look at PD-L1 expression and immunotherapies. Who are the best candidates for these therapies? Who should not receive them? Visit ...
S8:E1 – Oncology Morning Commute: Molecular Profiling in Non-Small Cell Lung Cancer
26 Mar 2022
Contributed by Lukas
Our faculty discuss molecular testing for non-small cell lung cancer (NSCLC). Should all patients with NSCLC be tested for biomarkers? Visit http://mo...
S7:E5 – Oncology Morning Commute: Clinical Trials—Ensuring Inclusivity
15 Mar 2022
Contributed by Lukas
In this episode our faculty discuss clinical trials in oncology. Are they reflective of the general population of patients who will ultimately be affe...
S7:E4 – Oncology Morning Commute: Disparities in Care
15 Mar 2022
Contributed by Lukas
In this episode, our faculty continues their discussion about disparities in oncology care. Is there a solution? How can being team-focused help patie...
S7:E3 – Oncology Morning Commute: Addressing Bias in Patient Care
15 Mar 2022
Contributed by Lukas
How does implicit bias impact patient care? What is unconscious bias and how can clinicians become more aware of their own biases is regard to patient...
S7:E2 – Oncology Morning Commute: Improving Equity in Healthcare
15 Mar 2022
Contributed by Lukas
In this episode our faculty will focus on health equity. What causes health inequity? Is it lack of access to care, cancer screenings, early diagnoses...
S7:E1 – Oncology Morning Commute: The Health Disparities Landscape
15 Mar 2022
Contributed by Lukas
In this episode, our faculty discuss disparities in oncology care. What exactly are health disparities? What populations are most at risk for experien...
S6:E6 – Oncology Morning Commute: The Emerging Role for Antibody-Drug Conjugates in GI Cancers
28 Feb 2022
Contributed by Lukas
In this podcast our faculty discuss gastrointestinal (GI) cancers and antibody-drug conjugates. How are these new therapies changing the landscape of ...
S6:E5 – Oncology Morning Commute: Targeted Therapies for Gastroesophageal and Colorectal Cancers
28 Feb 2022
Contributed by Lukas
HER2 expression in gastric/gastroesophageal junction and colorectal cancer potentially paves the way for the use of targeted therapies for these cance...
S6:E4 – Oncology Morning Commute: Targeting HER2, HER3, and TROP2 in NSCLC
28 Feb 2022
Contributed by Lukas
Our faculty continue their discussion on antibody-drug conjugates and look at some of the promising trials in NSCLC for these promising therapies. Vis...
S6:E3 – Oncology Morning Commute: ADCs for NSCLC—Ready for Prime Time?
28 Feb 2022
Contributed by Lukas
Our faculty discuss exciting developments in targeted therapies for non-small cell lung cancer, specifically the promise of antibody-drug conjugates a...
S6:E2 – Oncology Morning Commute: From HER2 Low to TROP2—Evolving Targeted Therapies for Breast Cancer
28 Feb 2022
Contributed by Lukas
Our faculty continue their discussion of antibody-drug conjugates. They look beyond targeting HER2 and review data on the treatment of metastatic trip...
S6:E1 – Oncology Morning Commute: Antibody Drug Conjugates and HER2-Positive Breast Cancer
28 Feb 2022
Contributed by Lukas
Our faculty discuss the exciting developments in antibody-drug conjugate therapy for human epidermal growth factor receptor 2-positive breast cancer. ...
S5:E6 – Multiple Myeloma Morning Commute: Tolerable and Sustainable Treatments for Multiple Myeloma
31 Mar 2021
Contributed by Lukas
Visit http://morningcommutepodcast.com/multiplemyeloma6 to view the activity and CME/CE information, download the transcript, and complete the posttes...
S5:E5 – Multiple Myeloma Morning Commute: New and Emerging Multiple Myeloma Treatments– Giving the Snowball a Chance
31 Mar 2021
Contributed by Lukas
Visit http://morningcommutepodcast.com/multiplemyeloma5 to view the activity and CME/CE information, download the transcript, and complete the posttes...
S5:E4 – Multiple Myeloma Morning Commute: BCMA as a Therapeutic Target for Multiple Myeloma
31 Mar 2021
Contributed by Lukas
Visit http://morningcommutepodcast.com/multiplemyeloma4 to view the activity and CME/CE information, download the transcript, and complete the posttes...
S5:E3 – Multiple Myeloma Morning Commute: Another Tool in the RRMM Toolbox
31 Mar 2021
Contributed by Lukas
Visit http://morningcommutepodcast.com/multiplemyeloma3 to view the activity and CME/CE information, download the transcript, and complete the posttes...
S5:E2 – Multiple Myeloma Morning Commute: Can We Do Better in Relapsed/Refractory Disease?
31 Mar 2021
Contributed by Lukas
Visit http://morningcommutepodcast.com/multiplemyeloma2 to view the activity and CME/CE information, download the transcript, and complete the posttes...
S5:E1 – Multiple Myeloma Morning Commute: Standard Care for the Newly Relapsed Patient
31 Mar 2021
Contributed by Lukas
Visit http://morningcommutepodcast.com/MultipleMyeloma1 to view the activity and CME/CE information, download the transcript, and complete the posttes...
S3:E3 – Non-Small Cell Lung Cancer Morning Commute: What’s on the Horizon?
11 Feb 2021
Contributed by Lukas
Visit MorningCommutePodcast.com/NSCLC3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation ...
S3:E2 – Non-Small Cell Lung Cancer Morning Commute: When and Why to Skip the Chemotherapy
11 Feb 2021
Contributed by Lukas
Visit MorningCommutePodcast.com/NSCLC2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation ...
S3:E1 – Non-Small Cell Lung Cancer Morning Commute: The Newly Diagnosed Patient
11 Feb 2021
Contributed by Lukas
Visit MorningCommutePodcast.com/NSCLC1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation ...
S2:E2 – Oncology Journal Club: Special Considerations in Chronic Lymphocytic Leukemia and Covid-19
25 Jan 2021
Contributed by Lukas
Visit http://journalclubpodcasts.com/cll to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluatio...
S2:E1 – Oncology Journal Club: Special Considerations in Clinical Oncology and Covid-19
04 Nov 2020
Contributed by Lukas
Visit journalclubpodcasts.com/clinicaloncology to view the activity and CME/CE information, download the transcript, and complete the posttest and eva...
S1:E3 – Endometrial Cancers Morning Commute: Matching the Right Treatment to the Right Patient
31 Jul 2020
Contributed by Lukas
Visit morningcommutepodcast.com/endometrial1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evalu...
S1:E2 – Endometrial Cancers Morning Commute: Immunotherapy - A New Player in Endometrial Cancer Treatment
31 Jul 2020
Contributed by Lukas
Visit morningcommutepodcast.com/endometrial2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evalu...